March 9, 2017
Researchers have known that part of the challenge in treating penicillin-resistant infections lies in understanding the way bacteria inactivate penicillin antibiotics. The enzymes that do this, beta-lactamases, chop up the antibiotics rendering them useless. One particularly problematic group of bacterial beta-lactamases, metallo-beta-lactamases (MBLs), is able to destroy even the newest penicillins. MBLs are often made by bacteria alongside other enzymes, including other beta-lactamases that allow certain bacteria to destroy the entire penicillin arsenal. Now, researchers in Cleveland, Ohio have taken a significant step toward defeating antibiotic-resistant infections by combining two different antibiotics that each block a different kind of drug-destroying enzyme secreted by bacteria. When combined, the antibiotics run interference for each other to fight infections. Now doctors have a new weapon to overcome one of the most pernicious infections caused by deadly bacteria endemic to hospitals.
CRE is shorthand for carbapenem-resistant enterobacteriaceae, which causes approximately one-third of healthcare-associated infections in the United States and kills nearly half its victims, according to a multicenter epidemiologic study just released in Antimicrobial Agents and Chemotherapy. The new combination antibiotic drug regimen proved effective against 81% of CRE specimens tested in a second study, published in the same journal issue. Both studies were conducted under the leadership of Robert A. Bonomo, MD, Professor of Medicine, Pharmacology, Biochemistry, Molecular Biology, and Microbiology at Case Western Reserve University School of Medicine and Chief of Medical Service at the Louis Stokes Cleveland Veterans Affairs Medical Center.
The strategy uses two antibiotic drugs to protect each other from being neutralized by CRE’s problematic enzymes. The first half of the antibiotic combination regimen—ceftazidime/avibactam—is vulnerable to the neutralizing effect of the metallo-beta-lactamases. But the other antibiotic in the regimen—aztreonam—is not. But aztreonam is, however, vulnerable to other types of CRE enzymes, which are in turn neutralized by ceftazidime/avibactam. So, when combined, the two antibiotics run interference for each other and in tag-team fashion defeat the infection.
The novel combination helps doctors overcome the antibiotic neutralizing metallo-beta-lactamases. With protection from the other half of the regimen, “aztreonam skirts around the metallo-beta-lactamase and hits its target—the penicillin-binding proteins,” Bonomo explained in a Center for Infectious Disease Research and Policy feature. Bacteria with aztreonam attached to their penicillin-binding proteins can’t build effective cell walls with the drug in the way, and they quickly die. Said Bonomo, “If we understand the fundamental mechanisms by which bacteria become resistant to antibiotics, we can use what we know to help design better therapies.”
Bonomo and his team demonstrated their regimen’s promise in laboratory models, but were soon faced with patients who had no other treatment options. Doctors necessarily used the new regimen to treat a young kidney transplant patient at Nationwide Children’s Hospital, and an elderly woman who had just received a new hip at University Hospitals. Both patients had various infections that verged on fatal, yet survived because of the cutting edge treatment.
The combination approach still needs to go through clinical trials and undergo additional research before it can become a commonly used treatment. It is however extremely promising news for doctors worldwide low on options to treat patients with antibiotic-resistant infections.
# # #
Funding for the ceftazidime/avibactam and aztreonam study was provided by grants from the National Institute of Allergy and Infectious Diseases (UM1AI104681, R01AI063517, R01AI072219, and R01AI100560 to R.A.B.; HHSN272201500007c to W.J.W.) and the Veteran Affairs Merit Review Program 1I01BX001974 to R.A.B.).
For more information about Case Western Reserve University School of Medicine, please visit: http://case.edu/medicine.
Founded in 1843, Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and is among the nation's top medical schools for research funding from the National Institutes of Health. The School of Medicine is recognized throughout the international medical community for outstanding achievements in teaching. The School's innovative and pioneering Western Reserve2 curriculum interweaves four themes--research and scholarship, clinical mastery, leadership, and civic professionalism--to prepare students for the practice of evidence-based medicine in the rapidly changing health care environment of the 21st century. Nine Nobel Laureates have been affiliated with the School of Medicine.
Annually, the School of Medicine trains more than 800 MD and MD/PhD students and ranks in the top 25 among U.S. research-oriented medical schools as designated by U.S. News & World Report's "Guide to Graduate Education."
The School of Medicine is affiliated with University Hospitals Cleveland Medical Center, MetroHealth Medical Center, the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, and the Cleveland Clinic, with which it established the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in 2002. case.edu/medicine.
Associate Dean, Marketing and Communications
The School of Medicine
Case Western Reserve University